Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4733)	7/4/1998 2:35:00 PM
From: billkirn	Read Replies (1) \| Respond to of 6136

Izzy: Conclusions from NYT on line article: nytsyn.com Agouron needs to demonstrate that Viracept has less of these fat attributes than others or they will fit in the same camp and eventually loose maker share. Come on PR people at Agouron.. Get to work and answer some of these current objections and concerns to PI therapy. And, while doing so, come up with a well presented case for the current huge expenditures on these new HIV drugs... We need to understand the various trade-offs and reasons behind these moves.. Unless this is done, I suspect the stock will get hit pretty hard over the next few months since earnings expectations are going to get smashed. Bill